Complex pathways to Ceftolozane-tazobactam resistance in clinical *Pseudomonas aeruginosa* isolates: a genomic epidemiology study

Hoai-An Nguyen[1], Anton Y. Peleg[1,2,3], Jiangning Song[3,4], Jessica A. Wisniewski[1†], Luke V. Blakeway[1†], Gnei Z. Badoordeen[1†], Ravali Theegala[1†], Nhu Quynh Doan[1], Matthew H. Parker[1], David L. Dowe[5] and Nenad Macesic*[1,3]

[1]Department of Infectious Diseases, The Alfred Hospital and School of Translational Medicine, Monash University, Melbourne, Australia.

[2]Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Melbourne, Australia.

[3]Centre to Impact AMR, Monash University, Melbourne, Australia

[4]Monash Biomedicine Discovery Institute, Department of Biochemistry & Molecular Biology, Monash University, Melbourne, Australia

[5]Department of Data Science & AI, Monash University, Melbourne, Australia.

* Corresponding Author

Nenad Macesic, Department of Infectious Diseases, The Alfred Hospital and School of Translational Medicine, Monash University, Level 1, The Alfred Lane House, 11 Alfred Ln, Melbourne, VIC 3004, Australia.

nenad.macesic1@monash.edu

†No longer at the institution where the work was performed.

Keywords:

Ceftolozane/tazobactam, antimicrobial resistance, *Pseudomonas aeruginosa*, genome-wide association studies, machine learning.

Abstract

Objectives

We aimed to conduct a comprehensive genomic analysis of ceftolozane/tazobactam (C/T) resistance mechanisms in *Pseudomonas aeruginosa* by combining novel institutional data with publicly available sequencing data.

Methods

We analyzed 1,682 *P. aeruginosa* isolates, comprising 339 isolates from Alfred Hospital (Melbourne, Australia) and 1,343 isolates from six public datasets. All isolates underwent whole-genome sequencing and C/T broth microdilution (BMD) susceptibility testing. We assessed previously reported intrinsic and acquired resistance mechanisms. We then conducted a genome-wide association study (GWAS) and machine learning analysis to identify novel genes associated with resistance. We then evaluated the impact of mutations in these genes on MIC values and ceftolozane binding affinity.

Results

Among 1,682 *P. aeruginosa* isolates representing 527 distinct sequence types, 343 (20.4%) were C/T-resistant. Carbapenemase genes were detected in 206/1,682 (12.2%) isolates. Mutations in previously reported resistance-associated genes (*ftsI, mpl, ampD, ampC, ampR, oprD)* were more frequent in resistant isolates but were also found in almost all susceptible

isolates. Successive mutations conferred additive increases in MIC. Combined GWAS and machine learning analyses *a priori* identified five key genes significantly associated with resistance: *ftsI*, *ampR*, *ampC*, PA3329, and PA4311. Molecular docking simulation revealed that the R504C mutation in penicillin-binding protein 3 (PBP3), which is encoded by *ftsI*, reduced binding contacts and hydrogen bonds with ceftolozane, significantly decreasing binding affinity (P=0.016).

Conclusions

Our analysis of 1,682 *P. aeruginosa* genomes demonstrated complex pathways to C/T resistance and showed that *ftsI* may play an underappreciated role. We discovered two previously unidentified genes associated with C/T resistance, whose function remains to be determined.

Introduction

Pseudomonas aeruginosa is a key Gram-negative pathogen, accounting for 9.4% of global antimicrobial resistance (AMR)-attributable deaths in 2021[1]. Multidrug-resistant (MDR) *P. aeruginosa* forms 15-30% of total *P. aeruginosa* infections[2], severely limiting available treatment options. Consequently, ceftolozane-tazobactam (C/T) has emerged as a first-line treatment for MDR *P. aeruginosa* infections[3]. However, rates of C/T resistance in MDR *P. aeruginosa* can be as high as 18.4%[4]. This highlights the urgent need to understand C/T resistance mechanisms, in order to rapidly identify resistant isolates and better control their spread.

There are multiple pathways contributing to C/T resistance[5]. Of these, structural alterations in AmpC β-lactamase represent most common mechanism[6-8]. AmpC hyperproduction, resulting from mutations in regulatory genes (*ampD*, *ampR*, and *dacB*), also confers resistance[6,7]. Acquired AMR genes such as carbapenemases or extended-spectrum β-lactamases represent another major mechanism due to their ability to hydrolyze ceftolozane[8,9]. Other mechanisms include mutations in *ftsI*, encoding penicillin-binding protein 3 (PBP3), and DNA polymerase subunits gama and tau[7,10].

Previous studies on C/T resistance have largely focused on case series and well-described mechanisms[7,8,11]. However, the complex interplay between different resistance mechanisms remains poorly understood, and the identification of novel resistance determinants has been limited. To address these gaps, we aimed to comprehensively determine C/T resistance mechanisms using novel data from our institution combined with all publicly-available *P. aeruginosa* genomes with matched C/T susceptibility phenotypes. Specifically, we aimed to

assess prevalence of known resistance mechanisms, then identify novel mechanisms through a genome-wide association study (GWAS) and machine learning (ML) approaches (**Figure 1**).

Materials and methods

Bacterial isolates collection

The study was reviewed and approved by the Alfred Hospital Ethics Committee (Project No. 185/21). We analysed *P. aeruginosa* isolates collected between 2004-2021 at the Alfred Hospital (Melbourne, Australia), a 638-bed quaternary hospital with a cystic fibrosis and lung transplant state referral service. All isolates underwent short-read sequencing (Illumina). We identified six public datasets containing both whole-genome sequencing (WGS) data and antimicrobial susceptibility testing (AST) results[5,10,12-15]. To ensure standardized resistance determination, we included only datasets where minimum inhibitory concentrations (MIC) were determined using broth microdilution (BMD), the reference method. The in-house sequence files have been deposited in NCBI project ID PRJNA1220180.

Antimicrobial susceptibility testing

For our in-house isolates, we conducted BMD using the ThermoFisher Sensititre plate (code: DKMGN) to determine C/T MIC values. We used the European Committee on Antimicrobial Susceptibility Testing (EUCAST) v15.0 breakpoints (MIC $\leq$4mg/L) to classify isolates as 'susceptible' or 'resistant'[16].

WGS data processing

De novo short-read assembly was generated using Unicycler v0.5.0[17]. Species confirmation and multi-locus sequence typing (MLST) were conducted via Pathogenwatch

(https://pathogen.watch). Acquired AMR genes were detected using AMRFinderPlus v3.11.18[18]. For chromosomal mutations analysis, we assessed mutations in ten genes previously linked to C/T resistance, as described by Cortes-Lara et al.[5]. Additionally, we included *oprD* due to its involvement in resistance following C/T exposure (see Supplementary Methods)[7].

Identifying variants associated with C/T resistance

We conducted GWAS on susceptible/resistant phenotypes using a mixed-effects model implemented in pyseer v1.3.10[19]. Unitigs were used as testing variants, with a phylogeny-based pairwise distance matrix incorporated to control for population structure. Association mapping was performed using the annotated PAO1 reference genome (Genbank: GCA_000006765.1). To reduce false positives and computational load, we applied a two-step filtering strategy: first identifying GWAS-significant variants, then retaining only those that also contributed to ML-based C/T resistance prediction (See Supplementary Methods).

Binding affinity analysis

We assessed the binding affinity between ceftolozane and proteins encoded by GWAS-significant genes, comparing both wild-type and mutant variants. 3D structures of proteins were predicted using ColabFold, an AlphaFold-based tool[20]. Molecular docking simulations were performed using AutoDock Vina v1.2.5[21], and results were visualised using PyMOL[22].

Results

Data characteristics

We analysed 1,682 *P. aeruginosa* isolates from four continents (Asia, Europe, North America, Oceania) (**Supplementary File 1**), including Alfred Hospital isolates (339/1,682, 20.2%) and six public datasets (1,343/1,682, 79.8%)[5,10,12-15]. C/T resistance was noted in 343/1,682 (20.4%) isolates. We detected 527 sequence types (STs) (**Supplementary Figure 1**). *P. aeruginosa* ST235, a well-recognised global MDR lineage was most frequent (163/1,682, 9.7%) and accounted for 78/343 (22.8%) of C/T resistant isolates. Resistance rates in common ST groups can be found in **Supplementary Table 1**.

Prevalence of acquired AMR genes

We first analysed acquired C/T resistance determinants. Carbapenemase genes were noted in 206/1,682 (12.2%) isolates (**Supplementary Table 2**), including serine carbapenemase (bla_{GES}, bla_{KPC}) and metallo-*β*-lactamase genes (bla_{IMP}, bla_{VIM}, bla_{NDM}). Carbapenemase acquisition strongly predicted C/T resistance, with 202/206 (98.1%) carbapenemase-positive isolates being C/T resistant. Only bla_{GES-5} was found in C/T-susceptible isolates (4/206, 1.9%). The most common carbapenemase was bla_{NDM-1} (37/206, 18.0%), followed by bla_{IMP-4} (31/206, 15.0%), bla_{IMP-1} (29/206, 14.1%), bla_{VIM-2} (25/206, 12.1%) and bla_{GES-5} (22/206, 10.7%). Dual carbapenemases were identified in six isolates. Analysis of OXA-type β-lactamases revealed 52 distinct genes (**Supplementary Figure 3**). Of these, bla_{OXA-10}, bla_{OXA-14}, $bla_{OXA-141}$, $bla_{OXA-210}$, $bla_{OXA-796}$ and $bla_{OXA-846}$ were significantly more prevalent in C/T-resistant isolates, with bla_{OXA-14}, $bla_{OXA-141}$, $bla_{OXA-210}$, and $bla_{OXA-796}$ found exclusively in resistant isolates. VEB-type β-lactamases were detected only in C/T-resistant isolates (8/343, 2.0%), with 4/8 co-harboring additional carbapenemases: two with bla_{KPC-2}, one with bla_{VIM-5}, and one with bla_{NDM-1}.

Analyses of known chromosomal C/T resistance mechanisms

We then assessed prevalence of mutations in a curated list of eleven intrinsic genes associated with C/T resistance (*ampC* and its regulators, mexAB-oprM overexpression pathway, *ftsI, galU* and *oprD*, **Figure 2A-C, Supplementary Table 3**)[5]. We specifically excluded isolates with acquired resistance determinants that likely conferred C/T resistance alone (carbapenemase genes, VEB-type β-lactamases, OXA-type β-lactamases with significantly higher prevalence in resistant isolates), as the impact of additional mutations would be unclear. This resulted in a subset of 1,442 isolates (including 114 resistant isolates), which we will refer to as the 'intrinsic resistance' dataset. Mutations in genes associated with resistance were noted in all resistant isolates but also in 1,319/1,328 (99.3%) susceptible isolates (**Supplementary Table 3**). For instance, *ampC* mutations were observed in 94.7% of resistant and 84.7% of susceptible isolates.

Given this high prevalence, we further focused on mutations with a previously reported high impact on C/T susceptibility. These were significantly more frequent in resistant than susceptible isolates (in order of significance): *ftsI* (24/114 resistant vs. 22/1,328 susceptible isolates, $P=2.70\times10^{-28}$), *mpl* (12/114 vs. 44/1,328, $P=3.53\times10^{-4}$), *ampD* (9/114 vs 37/1,328, P=0.007), *ampC* (53/114 vs 461/1,328, P=0.016), and *ampR* (12/114 vs 73/1,328, P=0.048). In terms of specific mutations, for *ftsI* the R504C mutation was most prevalent (21/114 [18.4%] resistant vs 17/1328 [1.3%] susceptible isolates). Notably, it was distributed across 18 unique STs in the resistant group. The previously reported F533L and E466K mutations were found in 1/114 (0.9%) and 0 C/T-resistant isolates, respectively[23,24]. For known *ampC* mutations[25], E247G and deletions in the G229-E247 region (△G at L237, △P241-A246, and △R238-

L244) were found in one and three resistant isolates, respectively, and in no susceptible isolates.

Inactivated *oprD* was also more frequent in resistant isolates (77/114 [67.5%] vs 623/1328 [50.5%], $P=3.60\times10^{-5}$). Frameshift due to indels was the most common mutation in both resistant (26/114, 22.8%) and susceptible (249/1328, 18.8%) isolates. For other canonical C/T resistant genes, mutations in the *mexAB-oprM* efflux pump regulators (*nalC*, *nalD*, and *mexR*) were very frequent in the resistant group, occurring in 110/114 (96.5%). Mutations in *galU* were noted in only 3/114 (2.6%) resistant isolates, while no mutations were detected in *dacB*.

Analysis of combinations of mutations in C/T resistance-associated genes revealed 53 distinct mutational pathways in resistant isolates (**Figure 2B**). Multiple mutations were common, with only 1/56 (1.8%) pathways involving a single mutation. Notably, all resistant isolates harbored at least one mutation in either *ampC* or its overexpression regulators (*ampR*, *ampD*, *mpl*). At the AMR mechanism level, collapsing *ampC*-related genes and *mexAB-oprM*-related genes into functional groups revealed seven distinct resistance pathways (Figure 2C). Among these, only modifications in AmpC and its regulatory genes emerged as a standalone pathway capable of conferring C/T resistance.

We next investigated the impact of multiple mutations on MIC, firstly by including both low- and high-impact mutations (**Figure 2D**, **Supplementary Figure 3A**), then high-impact mutations only (**Figure 2E**, **Supplementary Figure 3B**). We observed a monotonic increase in MIC with increasing number of mutations in both analyses. High-impact mutations were associated with higher MIC increases, with a single mutation able to achieve resistant MICs

(mean: 3.98 mg/L, SD: 10.33, **Figure 2E**) per EUCAST breakpoints (4 mg/L). When considering both low- and high-impact mutations, six or more mutations were required to achieve the same effect (**Figure 2D)**.

Identifying novel C/T resistance mechanisms through GWAS and ML analysis

Using the 'intrinsic resistance' dataset (n=1,442), we conducted GWAS and identified 290 significant variants out of 2,305,235 unitigs tested (Bonferroni-adjusted $P=2.17 \times 10^{-8}$; **Supplementary Figure 4**). Mapping to the PAO1 reference genome annotated 260 unitigs corresponding to 73 genes (**Supplementary Table 4**). Top associated genes included *ftsI* ($P=2.02\times10^{-23}$), *hsbR* ($P=3.33\times10^{-20}$), *ampR* ($P=2.71\times10^{-16}$), *ampC* ($P=4.32\times10^{-15}$), and several hypothetical proteins, including PA3329 ($P=1.00\times10^{-15}$), PA4311 ($P=5.55\times10^{-15}$), and PA2418 ($P=8.83\times10^{-14}$) (**Figure 3A**).

We then developed ML models to predict binary C/T resistance using the same dataset, achieving an average area under receiver operator curve (AUROC) of 0.65, and log-loss of 0.26 (**Supplementary Figure 5**). Across all model iterations, 369 unitigs were selected. To refine the list of candidates, we intersected GWAS-significant unitigs with those selected by the models, applying thresholds of a minimum allele frequency $\geq$0.1 and presence in at least 5 model iterations (**Figure 3B**, **Supplementary Table 4**). This filtering yielded five key genes: *ftsI* and *ampR* were selected in all models, while PA4311, PA3329, and *ampC* appeared in 8/10, 6/10, and 6/10 models, respectively.

Binding affinity assessment for significant variants

ftsI emerged as a key determinant of C/T resistance in analysis of known resistance mechanisms, as well as GWAS/ML analysis. These findings and the fact that PBP3 is a target of ceftolozane prompted investigation of mutation impacts on *in silico* binding affinity[26]. We identified four non-synonymous mutations in GWAS-significant unitigs mapped to *ftsI*: R504C (n=38), F507I (n=1), T514A (n=1), and R504H (n=1). Among these, only R504C was significantly associated with resistant isolates (21/114 [18.4%], $P=1.57\times10^{-26}$) while the others were exclusively found in susceptible isolates. Molecular docking analysis revealed significantly higher binding affinity between ceftolozane and wild type PBP3 compared to mutant PBP3 (R504C) (-3.520 vs -2.814 kcal/mol, P=0.016) (**Supplementary Figure 6**), with loss of contact at A244 and single hydrogen bonds at Q265 and T267 (cf. double bonds in wild type PBP3) (**Figure 4**). These changes potentially explain reduced drug binding and consequent resistance.

We extended our docking analysis to the novel proteins encoded by PA3329 and PA4311. The PA3329-encoded protein showed no meaningful binding affinity to ceftolozane (mean: 924.393 kcal/mol, SD: 288.148). The PA4311-encoded protein demonstrated binding affinity (-1.493 kcal/mol, 1.459) with potential binding sites at D116, Q271, R292 and G294 (**Supplementary Figure 7**).

Discussion

This comprehensive genomic analysis of 1,682 *P. aeruginosa* isolates has revealed multiple mechanisms contributing to C/T resistance, including previously known resistance determinants (*ftsI*, *ampC*, and *ampR*) and novel candidates (PA3329 and PA4311). *ftsI* emerged as a key contributor to C/T resistance across multiple analyses. These findings were

underscored by several methodological strengths. Our study leveraged a large, geographically diverse dataset incorporating both novel and public genome sequences to provide robust statistical power and broad representativeness. Additionally, our multi-modal approach, which combines GWAS, ML, and molecular docking, enabled cross-validation of findings through complementary methodologies.

Ceftolozane is a potent inhibitor of PBP3 encoded by *ftsI*[26]. Our study noted that mutations in *ftsI* were highly associated with C/T resistance, being present in 24/114 resistant vs 22/1,328 susceptible isolates ($P=2.70\times10^{-28}$), specifically the R504C mutation. This was then further confirmed in our GWAS and ML analyses, which both identified *ftsI* as the top-ranking contributor to C/T resistance. Our docking analysis then demonstrated that mutant *ftsI* (R504C) significantly reduced ceftolozane binding affinity, providing a mechanistic explanation for resistance. The role of PBP3 in β-lactam resistance has been increasingly recognised, not only in *P. aeruginosa*[7], but also across various Enterobacterales[27,28]. Although the R504C mutation was previously documented to emerge following C/T exposure[11], its importance in C/T resistance has been potentially underappreciated, as research has primarily focused on β-lactamases[8,29]. Furthermore, its co-occurrence with other mutations may have obscured its individual contribution to resistance[7,8,11], highlighting the value of GWAS approach in identifying specific resistance determinants.

Our analysis of genes previously associated with C/T resistance[5] showed that they likely have differing contributions when studied in a diverse international dataset. We applied a multi-modal approach to assess the contribution of resistance genes by applying both a traditional genomic analysis looking at genes associated with C/T resistance in the literature, and GWAS

and ML approaches to allow us to identify key resistance genes *a priori.* Mutations in *ampC* and its regulator genes were found in all resistant isolates. Amongst these some were confirmed to have strong contributory effects (e.g. *ampC* and *ampR*) but others contributed less (e.g. GWAS suggested limited contributions from *ampD*). In some C/T resistance genes we detected very few mutations (e.g. *galU* in 2.6% of resistant isolates) and in some we did not detect mutations at all (*dacB).* These findings highlight the complex nature of C/T resistance mechanisms in *P. aeruginosa*. To try to account for some of these interactions, we assessed the impact of multiple mutations and noted step-wise increases in MIC with the number of mutations, both when considering all non-synonymous mutations and when considering high-impact mutations alone.

The contribution of horizontally acquired β-lactamase genes to C/T resistance has been well described[8,9], specifically key carbapenemases including bla_{VIM}, bla_{IMP}, bla_{NDM}, and bla_{KPC}. While we noted these carbapenemases in 12.2% isolates in our study, we also showed that specific bla_{OXA} and bla_{VEB} genes may play an important role. Four bla_{OXA} genes ($bla_{\mathrm{OXA\text{-}14}}$, $bla_{\mathrm{OXA\text{-}141}}$, $bla_{\mathrm{OXA\text{-}210}}$, and $bla_{\mathrm{OXA\text{-}796}}$) and all bla_{VEB} genes were found exclusively in resistant isolates. These findings confirm prior studies that identified bla_{OXA} gene acquisition as a common cause of C/T resistance (particularly $bla_{OXA\text{-}14}$)[8], as well as noting an association between bla_{VEB} gene acquisition and C/T resistance[30].

Our study had several limitations. Firstly, the retrospective nature of the analysis and potential sampling bias in the dataset may affect generalizability. Secondly, functional validation of novel genetic determinants PA3329 and PA4311 is crucial to understand their role in resistance. While PA3329 has not been previously associated with C/T resistance, mutations

in PA4311 have been observed following seven days of C/T exposure[6]. However, the emergence of mutations in multiple genes complicates the identification of key resistance drivers. Although tools like AlphaFold offer advances in structure and binding prediction, computational inference of protein function, particularly for hypothetical proteins, remains limited. Lastly, while docking analysis suggests reduced ceftolozane binding to mutant PBP3, in vitro studies are required to confirm these findings.

In conclusion, our study rigorously determined the genetic underpinnings of C/T resistance and revealed complex pathways leading to C/T resistance. *ampC* and its regulators were confirmed to play an important role but we demonstrated that *ftsI* may be a more significant contributor than previously recognized. We also identified two novel determinants whose functions remains to be determined. The hypotheses generated by our study present an opportunity for validation through both computational and experimental approaches to understand the functional mechanisms of these newly identified determinants.

Author contributions

HA.N, N.M. and A.Y.P. conceived the study. J.A.W. designed and supervised sampling and collection of bacterial isolates. J.A.W., L.V.B., G.Z.B, R.T., N.Q.D., and M.H.P. collected the bacterial isolates, performed bacterial characterization, conducted genome sequencing and broth microdilution. HA.N. preprocessed WGS data. HA.N., J.S., D.L.D., and N.M. conceptualized machine learning analyses. HA.N. conducted GWAS, developed machine learning models. HA.N. and N.M. analyzed all results. HA.N. and N.M. wrote the manuscript with comments and feedback of all of the co-authors. All authors read and approved the manuscript.

Funding

This work was supported by the National Health and Medical Research Council of Australia (Emerging Leader 1 Fellowship APP1176324 to N.M. and Practitioner Fellowship APP1117940 to A.Y.P) and the Australian Medical Research Future Fund (FSPGN000048). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Competing interests

N.M. has received research support from GlaxoSmithKline, unrelated to the current study. A.Y.P. has received research funding from MSD through an investigator-initiated research project. All other authors declare no conflict of interest.

Acknowledgement

This work was supported by Monash eResearch Centre, including the M3 service. This work was also supported by use of the Nectar Research Cloud, a collaborative Australian research platform supported by the NCRIS-funded Australian Research Data Commons (ARDC).

References

1. Naghavi M, Vollset SE, Ikuta KS, et al. Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050. *The Lancet*. 2024;404(10459):1199-1226. doi:10.1016/S0140-6736(24)01867-1
2. Horcajada JP, Montero M, Oliver A, et al. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant *Pseudomonas aeruginosa* Infections. *Clinical Microbiology Reviews*. 2019;32(4):10.1128/cmr.00031-19. doi:doi:10.1128/cmr.00031-19
3. Macesic N, Uhlemann A-C, Peleg AY. Multidrug-resistant Gram-negative bacterial infections. *The Lancet*. 2025;405(10474):257-272. doi:10.1016/S0140-6736(24)02081-6

4. Kostoulias X, Chang CC, Wisniewski J, et al. Antimicrobial susceptibility of ceftolozane-tazobactam against multidrug-resistant *Pseudomonas aeruginosa* isolates from Melbourne, Australia. *Pathology*. 2023;55(5):663-668. doi:10.1016/j.pathol.2023.03.009

5. Cortes-Lara S, Barrio-Tofiño Ed, López-Causapé C, et al. Predicting *Pseudomonas aeruginosa* susceptibility phenotypes from whole genome sequence resistome analysis. *Clinical Microbiology and Infection*. 2021;27(11):1631-1637. doi:10.1016/j.cmi.2021.05.011

6. Cabot G, Bruchmann S, Mulet X, et al. *Pseudomonas aeruginosa* Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC. *Antimicrobial Agents and Chemotherapy*. 2014;58(6):3091-3099. doi:doi:10.1128/aac.02462-13

7. Tamma PD, Beisken S, Bergman Y, et al. Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance. *Clinical Infectious Diseases*. 2020;73(11):e4599-e4606. doi:10.1093/cid/ciaa1306

8. Fraile-Ribot PA, Cabot G, Mulet X, et al. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR *Pseudomonas aeruginosa*. *Journal of Antimicrobial Chemotherapy*. 2017;73(3):658-663. doi:10.1093/jac/dkx424

9. Karlowsky JA, Lob SH, Estabrook MA, et al. Susceptibility profile and β-lactamase content of global *Pseudomonas aeruginosa* isolates resistant to ceftolozane/tazobactam and/or imipenem/relebactam—SMART 2016–21. *JAC-Antimicrobial Resistance*. 2023;5(3)doi:10.1093/jacamr/dlad080

10. del Barrio-Tofiño E, Zamorano L, Cortes-Lara S, et al. Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology. *Journal of Antimicrobial Chemotherapy*. 2019;74(7):1825-1835. doi:10.1093/jac/dkz147

11. Rubio AM, Kline EG, Jones CE, et al. *In Vitro* Susceptibility of Multidrug-Resistant *Pseudomonas aeruginosa* following Treatment-Emergent Resistance to Ceftolozane-Tazobactam. *Antimicrobial Agents and Chemotherapy*. 2021;65(6):10.1128/aac.00084-21. doi:doi:10.1128/aac.00084-21

12. Barrio-Tofiño Ed, López-Causapé C, Cabot G, et al. Genomics and Susceptibility Profiles of Extensively Drug-Resistant *Pseudomonas aeruginosa* Isolates from Spain. *Antimicrobial Agents and Chemotherapy*. 2017;61(11):10.1128/aac.01589-17. doi:doi:10.1128/aac.01589-17

13. Teo Jocelyn Q-M, Lim Jie C, Tang Cheng Y, et al. Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa. *mSphere*. 2021;6(1):10.1128/msphere.01026-20. doi:10.1128/msphere.01026-20

14. Stanton RA, Campbell D, McAllister GA, et al. Whole-Genome Sequencing Reveals Diversity of Carbapenem-Resistant *Pseudomonas aeruginosa* Collected through CDC's Emerging Infections Program, United States, 2016-2018. *Antimicrobial Agents and Chemotherapy*. 2022;66(9):e00496-22. doi:doi:10.1128/aac.00496-22

15. Sastre-Femenia MÀ, Fernández-Muñoz A, Gomis-Font MA, et al. *Pseudomonas aeruginosa* antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: a nation-wide five-year time lapse analysis. *The Lancet Regional Health – Europe*. 2023;34doi:10.1016/j.lanepe.2023.100736

16. European Committee on Antimicrobial Susceptibility Testing (EUCAST). *Breakpoint tables for interpretation of MICs and zone diameters. Version 15.0, valid from 2025-01-01*. 2023.

17. Wick RR, Judd LM, Gorrie CL, Holt KE. Unicycler: Resolving bacterial genome assemblies from short and long sequencing reads. *PLOS Computational Biology*. 2017;13(6):e1005595. doi:10.1371/journal.pcbi.1005595

394 18. Feldgarden M, Brover V, Gonzalez-Escalona N, et al. AMRFinderPlus and the Reference Gene
395 Catalog facilitate examination of the genomic links among antimicrobial resistance, stress response,
396 and virulence. *Scientific Reports*. 2021/06/16 2021;11(1):12728. doi:10.1038/s41598-021-91456-0
397 19. Lees JA, Galardini M, Bentley SD, Weiser JN, Corander J. pyseer: a comprehensive tool for
398 microbial pangenome-wide association studies. *Bioinformatics*. 2018;34(24):4310-4312.
399 doi:10.1093/bioinformatics/bty539
400 20. Mirdita M, Schütze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M. ColabFold: making
401 protein folding accessible to all. *Nature Methods*. 2022/06/01 2022;19(6):679-682.
402 doi:10.1038/s41592-022-01488-1
403 21. Eberhardt J, Santos-Martins D, Tillack AF, Forli S. AutoDock Vina 1.2.0: New Docking Methods,
404 Expanded Force Field, and Python Bindings. *Journal of Chemical Information and Modeling*.
405 2021/08/23 2021;61(8):3891-3898. doi:10.1021/acs.jcim.1c00203
406 22. Schrödinger LLC. The PyMOL Molecular Graphics System, Version 1.8. 2015.
407 23. Hernández-García M, García-Castillo M, García-Fernández S, et al. Distinct epidemiology and
408 resistance mechanisms affecting ceftolozane/tazobactam in *Pseudomonas aeruginosa* isolates
409 recovered from ICU patients in Spain and Portugal depicted by WGS. *Journal of Antimicrobial*
410 *Chemotherapy*. 2020;76(2):370-379. doi:10.1093/jac/dkaa430
411 24. Simner PJ, Beisken S, Bergman Y, Posch AE, Cosgrove SE, Tamma PD. Cefiderocol Activity Against
412 Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance. *Open Forum*
413 *Infectious Diseases*. 2021;8(7):ofab311. doi:10.1093/ofid/ofab311
414 25. Díaz-Cañestro M, Periañez L, Mulet X, et al. Ceftolozane/tazobactam for the treatment of
415 multidrug resistant *Pseudomonas aeruginosa*: experience from the Balearic Islands. *European Journal*
416 *of Clinical Microbiology & Infectious Diseases*. 2018/11/01 2018;37(11):2191-2200.
417 doi:10.1007/s10096-018-3361-0
418 26. Moyá B, Zamorano L, Juan C, Ge Y, Oliver A. Affinity of the New Cephalosporin CXA-101 to
419 Penicillin-Binding Proteins of *Pseudomonas aeruginosa*. *Antimicrobial Agents and Chemotherapy*.
420 2010;54(9):3933-3937. doi:doi:10.1128/aac.00296-10
421 27. Le Terrier C, Nordmann P, Buchs C, Poirel L. Effect of modification of penicillin-binding protein 3
422 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam,
423 aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing
424 broad-spectrum β-lactamases. *Antimicrobial Agents and Chemotherapy*. 2024;68(4):e01548-23.
425 doi:10.1128/aac.01548-23
426 28. Mushtaq S, Vickers A, Woodford N, Livermore DM. Activity of aztreonam/avibactam and
427 ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem
428 resistance. *International Journal of Antimicrobial Agents*. 2024/03/01/ 2024;63(3):107081.
429 doi:https://doi.org/10.1016/j.ijantimicag.2023.107081
430 29. Gomis-Font MA, Cabot G, López-Argüello S, et al. Comparative analysis of in vitro dynamics and
431 mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in
432 Pseudomonas aeruginosa XDR high-risk clones. *Journal of Antimicrobial Chemotherapy*.
433 2022;77(4):957-968. doi:10.1093/jac/dkab496
434 30. Livermore DM, Mushtaq S, Ge Y, Warner M. Activity of cephalosporin CXA-101 (FR264205)
435 against *Pseudomonas aeruginosa* and *Burkholderia cepacia* group strains and isolates. *International*
436 *Journal of Antimicrobial Agents*. 2009/11/01/ 2009;34(5):402-406.
437 doi:https://doi.org/10.1016/j.ijantimicag.2009.03.021
438



Figure 1. Overall workflow of the study. This figure was created with BioRender.com.


A.
oprD loss
Chromosomal mutations
All mutations
High impact on gene functionality
-log10(p-value)
P=0.05
oprD
ampC
ampD
ampR
mpl
mexR
nalD
nalC
ftsI
galU
No Mutation
Mutation
Distinct pathways
C.
AmpC modification & overexpression (ampC, ampR, ampD, mpl)
MexAB-OprM overexpression (mexR, nalD, nalC)
Penicillin-binding protein PBP3 (ftsI)
Lipopolysacharide synthesis (galU)
Porin loss (oprD)
Distinct pathways
D.
MIC (mg/L)
EUCAST breakpoint
Number of mutations (All non-synonymous mutations)
E.
MIC (mg/L)
EUCAST breakpoint
Number of mutations (High impact mutations)

442

Figure 2. (A) Impact of mutations in chromosomal genes known to affect C/T susceptibility. P-values were calculated using the Chi-square test. **(B) Pathways to C/T resistance at gene level.** Each unique combination of mutations in genes associated with C/T resistance is shown as a unique pathway. **(C) Distinct pathways to C/T resistance, collapsed to resistance mechanisms.** Here, the genes associated with C/T resistance are collapsed into mechanistic groupings. Each unique combination of mutations in mechanistic groupings is shown as a unique pathway. **(D, E) MIC values with respect to the cumulation of mutations (all non-synonymous mutations [D] vs high-impact mutations only [E]) in chromosomal genes known for C/T resistance.** Dots and vertical bars indicate mean and standard deviation (SD) of MIC values, respectively.



Figure 3. (A) Genes selected by GWAS study, with the maximum P-value (y-axis) and the average minimum allele frequency (MAF) (x-axis). (B) Genes (y-axis) selected by both GWAS and ML approach, and their occurrence in ML models (x-axis).



Figure 4. 3D structure visualization of the interaction of ceftolozane (pink) to R504C mutant PBP3 (Panel A) and wild type PBP3 (Panel B). Dashed yellow lines indicate hydrogen bonds. The R504C mutant (**Panel A**) shows loss of contact at A244 and single hydrogen bonds at positions Q265 and T267 (cf. double bonds in wild type PBP3 – **Panel B**).